Copyright © 2019. Inderes Oy. All rights reserved.

Orion

Analyst

Petri Kajaani

Petri Kajaani

Analyytikko

Read more

Company annual reports

Latest insider trading

Net impact profile

Stock release
21.10.
2020

ORION CORPORATION     STOCK EXCHANGE RELEASE   21 OCTOBER 2020 at 6.40  p.m. EEST

Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:

Stock release
21.10.
2020

ORION CORPORATION            INTERIM REPORT 1-9/2020    21 OCTOBER 2020 at 12:00 noon EEST

 

Orion Group Interim Report 1-9/2020

Stock release
19.10.
2020

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION 19 OCTOBER 2020 at 20.35 EEST             
         

Orion upgrades full-year outlook for 2020

Orion Corporation upgrades the full-year outlook for 2020, provided on 8 July 2020, both for the part regarding net sales and operating profit. In 2020, the net sales are estimated to be at a similar level as in 2019 or slightly higher than in 2019. Operating profit is estimated to be higher or clearly higher than in 2019.

Stock release
19.10.
2020

ORION CORPORATION                 PRESS RELEASE                19 OCTOBER 2020   at  2.15 p.m. EEST

Orion's statutory co-operation negotiations completed regarding the Research & Development function


Orion announced on 10 September 2020 that it is planning to change and refocus the strategy of its R&D function. The co-operation negotiations in Finland
related to these changes have been completed. As a result of the negotiations, 13 persons will be given a notice.

Stock release
19.10.
2020

ORION CORPORATION STOCK EXCHANGE RELEASE 19 OCTOBER 2020 at 9.00 EEST             
         

120,939 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 120,939 A shares have been converted into 120,939 B shares. The conversion has been entered into the Trade Register on 19 October 2020.

Stock release
6.10.
2020

ORION CORPORATION PRESS RELEASE 6 OCTOBER 2020 at 15.00 EEST             
         
Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020

Stock release
10.9.
2020

ORION CORPORATION                 PRESS RELEASE                10 SEPTEMBER 2020   at 2.00 p.m. EEST

Orion is planning to renew its R&D strategy and organisation

Orion is planning to change and refocus the strategy of its R&D function. The planned changes and renewal of the organisation are intended to strengthen the company's R&D portfolio and speed up the progress of research projects. The changes will affect the entire R&D organisation, and the company will launch co-operation negotiations on this in Finland.

Stock release
10.9.
2020

ORION CORPORATION PRESS RELEASE 10 SEPTEMBER 2020 at 7.30 EEST             
         
New England Journal of Medicine publishes final overall survival data for darolutamide showing treatment significantly extends life in men with non-metastatic prostate cancer

Stock release
31.7.
2020

ORION CORPORATION      MANAGERS’ TRANSACTIONS 31th July 2020 at 15.30 EEST

Orion Corporation: Managers’ transactions – Jari Karlson

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Stock release
28.7.
2020

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION   
28  JULY 2020 at 9.45 p.m. EEST             
         

Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan in treatment of ALS patients did not reach its pre-specified endpoints

Orion has completed the clinical phase 3 REFALS trial evaluating the efficacy and safety of oral levosimendan in the treatment of ALS (amyotrophic lateral sclerosis).

Orion

Orion lyhyesti

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.